1. Beyond the Abstract - Sorafenib and Surgical Complications: A Case Report of Adverse Reaction to Sorafenib during Treatment for Renal Cell Carcinoma
(Browse Categories/Beyond the Abstract - Renal Cancer)

BERKELEY, CA (UroToday.com) - In order to validate our observation that Sorafenib was the cause of the gross changes seen in the ileostomy, full thickness biopsies of the ileostomy were taken shortly

2. EAU 2008 - Sorafenib Plus Interferon-α2a in Metastatic Renal Cell Carcinoma: Results from RAPSODY (GOIRC Study 0681) - A Randomized Prospective Phase II Trial of Two Different Treatment Schedules
(Browse Categories/Renal Cancer)

MILAN, ITALY (UroToday.com) - Sorafenib is an oral multi-kinase inhibitor that has demonstrated efficacy in metastatic renal cell carcinoma (MRCC). The pleiotropic molecule interferon-α2a (IFN) has a

3. EAU 2008 - Sorafenib Plus Interferon-α2a in Metastatic Renal Cell Carcinoma: Results from RAPSODY (GOIRC Study 0681) - A Randomized Prospective Phase II Trial of Two Different Treatment Schedules
(Conference Coverage/EAU 2008 - Renal Cancer Highlights)

MILAN, ITALY (UroToday.com) - Sorafenib is an oral multi-kinase inhibitor that has demonstrated efficacy in metastatic renal cell carcinoma (MRCC). The pleiotropic molecule interferon-α2a (IFN) has a

4. ASCO 2008 Annual Meeting - Safety and Efficacy of Sorafenib in Elderly Patients (pts) >65 Years: A Subset Analysis from the Advanced Renal Cell Carcinoma Sorafenib (ARCCS) Expanded Access Program in North America
(Conference Coverage/ASCO 2008 - Kidney Cancer Abstracts)

...abrail, D. F. McDermott, L. Cupit, W. H. Miller, J. D. Hainsworth, C. W. Ryan, Advanced Renal Cell Carcinoma Sorafenib (ARCCS) Expanded Access Program in North America Background: Sorafeni...

5. EAU 2008 - Sorafenib Monotherapy in Patients with Metastatic Renal Cell Cancer: A Phase II Intra-Patient Dose Escalation Study
(Browse Categories/Renal Cancer)

MILAN, ITALY (UroToday.com) - Sorafenib 400 mg b.i.d. has shown anti-tumor activity and favorable tolerability in patients with metastatic renal cell carcinoma (RCC), allowing investigation of more in

6. EAU 2008 - Sorafenib Monotherapy in Patients with Metastatic Renal Cell Cancer: A Phase II Intra-Patient Dose Escalation Study
(Conference Coverage/EAU 2008 - Renal Cancer Highlights)

MILAN, ITALY (UroToday.com) - Sorafenib 400 mg b.i.d. has shown anti-tumor activity and favorable tolerability in patients with metastatic renal cell carcinoma (RCC), allowing investigation of more in

7. Bayer And Onyx Announce Nexavar® (Sorafenib Tosylate) Tablets As Global Trade Name For Investigational Cancer Treatment
(Browse Categories/Renal Cancer)

...ration (NYSE: BAY) and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced the selection of Nexavar® (sorafenib tosylate) Tablets as the global trade name for sorafenib, the oral investigationa...

8. Phase I Trial of Sorafenib in Combination with IFN -2a in Patients with Unresectable and/or Metastatic Renal Cell Carcinoma or Malignant Melanoma
(Browse Categories/Renal Cancer)

...al cell carcinoma (RCC) has been revolutionized by the introduction of targeted therapies like sunitinib and sorafenib that target multiple tyrosine kinases, which is important in RCC biology.Sorafeni...

9. √ Sorafenib In Renal Cell Carcinoma: Results Of the Phase II Placebo-Controlled Randomized Discontinuation Trial
(Browse Categories/Renal Cancer)

√ Editor's Pick:     BERKELEY, CA (UroToday.com) - Sorafenib was recently approved by the FDA as a systemic therapy option for metastatic renal cell carcinoma (RCC) in part due to

10. Sorafenib Slows Disease Progression in Kidney Cancer
(Browse Categories/Renal Cancer)

ORLANDO (Reuters Health) - The dual-action kinase inhibitor sorafenib lengthens progression-free survival in patients with metastatic renal cell carcinoma (RCC), according to preliminary results of a

11. √ A Phase II Clinical Trial of Sorafenib in Androgen-Independent Prostate Cancer
(Browse Categories/Prostate Cancer)

...n the January 1, 2008 issue of Clinical Cancer Research, Dr. Dahut and colleagues report a Phase II trial of Sorafenib in androgen-independent prostate cancer (AICaP). Sorafenib is an oral, multikina...

12. EAU 2008 - A Large Open-Label, Non-Comparative, Phase III Study of the Multi-Targeted Kinase Inhibitor Sorafenib in European Patients with Advanced Renal Cell Carcinoma
(Conference Coverage/EAU 2008 - Renal Cancer Highlights)

MILAN, ITALY (UroToday.com) - Dr. Verzoni presented a trial to collect safety and efficacy data on sorafenib from a large and broad study population reflecting clinical practice. This nonrandomize

13. EAU 2008 - A Large Open-Label, Non-Comparative, Phase III Study of the Multi-Targeted Kinase Inhibitor Sorafenib in European Patients with Advanced Renal Cell Carcinoma
(Browse Categories/Renal Cancer)

MILAN, ITALY (UroToday.com) - Dr. Verzoni presented a trial to collect safety and efficacy data on sorafenib from a large and broad study population reflecting clinical practice. This nonrandomize

14. ASCO 2008 Annual Meeting - Sequential Axitinib (AG-013736) Therapy of Patients (pts) with Metastatic Clear Cell Renal Cell Cancer (RCC) Refractory to Sunitinib and Sorafenib, Cytokines and Sorafenib, or Sorafenib Alone
(Conference Coverage/ASCO 2008 - Other: Genitourinary Cancer Abstracts)

...ic RCC refractory to prior multiple sequential therapies is of clinical interest. Methods: Pts with sorafenib-refractory (progression or unacceptable toxicity) metastatic RCC and measurable d...

15. √ Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
(Browse Categories/Renal Cancer)

...gues for the TARGET Study Group report the results of a Phase III trial designed to evaluate the efficacy of sorafenib in metastatic renal cancer.Sorafenib, approved by the FDA in December 2005 is an ...